Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D. Blaise D, et al. Among authors: bellanger c. Leuk Lymphoma. 1997 May;25(5-6):469-78. doi: 10.3109/10428199709039034. Leuk Lymphoma. 1997. PMID: 9250817 Clinical Trial.
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL, Stoppa AM, Payen C, Marit G, Bouabdallah R, Sotto JJ, Rossi JF, Brandely M, Hercend T, Maraninchi D. Blaise D, et al. Among authors: bellanger c. Eur Cytokine Netw. 2000 Mar;11(1):91-8. Eur Cytokine Netw. 2000. PMID: 10705305 Free article. Clinical Trial.
p53 regulates CD46 expression and measles virus infection in myeloma cells.
Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C. Lok A, et al. Among authors: bellanger c. Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106. Blood Adv. 2018. PMID: 30530776 Free PMC article.
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C, Maiga S, Touzeau C, Bellanger C, Kervoëlen C, Descamps G, Maillet L, Moreau P, Pellat-Deceunynck C, Gomez-Bougie P, Amiot M. Seiller C, et al. Among authors: bellanger c. Cell Death Dis. 2020 May 5;11(5):316. doi: 10.1038/s41419-020-2505-1. Cell Death Dis. 2020. PMID: 32371863 Free PMC article.
The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
Decombis S, Papin A, Bellanger C, Sortais C, Dousset C, Le Bris Y, Riveron T, Blandin S, Hulin P, Tessoulin B, Rouel M, Le Gouill S, Moreau-Aubry A, Pellat-Deceunynck C, Chiron D. Decombis S, et al. Among authors: bellanger c. Haematologica. 2022 Dec 1;107(12):2905-2917. doi: 10.3324/haematol.2021.279800. Haematologica. 2022. PMID: 35263985 Free PMC article.
Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma.
Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I, Chiron D, Bellanger C, Fleury C, Gélébart P, McCormack E, Ledoux D, Thieblemont C, Marzec J, Gribben JG, Cymbalista F, Varin-Blank N, Gardano L, Baran-Marszak F. Lazarian G, et al. Among authors: bellanger c. Oncogene. 2020 Apr;39(14):2934-2947. doi: 10.1038/s41388-020-1183-x. Epub 2020 Feb 7. Oncogene. 2020. PMID: 32034308
75 results